Business Report

As of June 30, 2026

Lunit

Disclaimer

This English translation has been prepared by Lunit Inc. solely for informational and reference purposes based on the Korean version of the Business Report. The financial information included herein has been prepared in accordance with Korean International Financial Reporting Standards (K-IFRS), and the financial information for the first half of 2026 has been reviewed by the Company's independent auditors.

In the event of any discrepancy or inconsistency between the Korean version and this English translation, the Korean version shall prevail. The Company does not undertake any obligation to update or revise this English translation to reflect events or circumstances after the date hereof.

I. Company History

2013	• Foundation of the company (as CLDI)
2014	• Seed Investment by Kakao Ventures ($0.1M)
2015	• Pivots to medical imaging – Changes name to Lunit • Series A investment led by Softbank Ventures Asia ($2M)
2016	• Series A1 investment led by Softbank Ventures Asia ($3.3M) • Ranked 1st place in MICCAI Tumor Proliferation Assessment Challenge 2016
2017	• **Top 100 AI Startup**, by CB Insights (Only Korean company selected) • Ranked 1st place in CAMELYON Grand Challenge 2017
2018	• Series B investment led by Intervest ($15M) • Ministry of Korea Food and Drug Safety (MFDS) clearance - **Lunit INSIGHT CXR Nodule** • Established Lunit subsidiary, Lunit USA in the U.S.
2019	• MFDS clearance - **Lunit INSIGHT MMG** • Signed AI solution distribution and supply partnership with Fujifilm • Series B1 investment led by Fujifilm ($5M) • MFDS clearance - **Lunit INSIGHT CXR MCA** • **Digital Health 150**, by CB Insights (Only Korean company selected) • Ranked 1st place in Visual Domain Adaptation Challenge • Series C-Tranche A investment led by Shinhan Investment ($27M)
2020	• CE marked in Europe - **Lunit INSIGHT MMG** • **Technology Pioneer 2020**, by World Economic Forum (Davos Forum, Only Korean company selected) • Signed AI solution distribution and supply partnership with GE Healthcare • **Digital Health 150**, by CB Insights (Only Korean company selected)
2021	• Signed AI solution distribution and supply partnership with Agfa • Signed AI solution distribution and supply partnership with Philips • Signed AI solution joint research partnership with Guardant Health • Series C-Tranche B investment by Guardant Health ($26M) • U.S. FDA clearance - **Lunit INSIGHT CXR Triage, Lunit INSIGHT MMG** • Certified as World Class Product of Korea by Ministry of Trade, Industry, and Energy - **Lunit INSIGHT** • **The 1st Government award for Innovative Medical Devices** Commendation of the Minister of Health and Welfare • Pre-IPO round investment led by HealthQuest and Naver ($61M) • **Digital Health 150**, by CB Insights (Only Korean company selected)
2022	• CE marked in Europe - **Lunit SCOPE PD-L1 TPS** • Signed joint bidding agreement with Hologic • Initial Public Offering - **KOSDAQ** • **Unicorn Community**, by World Economic Forum (Davos Forum) • Selected as the preferred AI technology for Australian National Breast Screen New South Wales (BSNSW)

2023	• Launched in Europe - **Lunit INSIGHT DBT** • Established Lunit subsidiary, Lunit Europe Holdings in Europe • 2023 Science, Information and Communication Day - **Science and Technology Promotion Division Presidential Commendation** • CXR-AID officially included as an eligible solution for health insurance reimbursement in Japan • U.S. FDA clearance - **Lunit INSIGHT DBT** • **Lunit INSIGHT CXR** - Authorized as Innovative Medical Technology • **Associate Partner**, by World Economic Forum (Davos Forum)
2024	• **Lunit INSIGHT MMG** - Designated as a New Health Technology (evaluation deferred) • Acquired 100% stake in **Volpara Health Technologies Ltd.** based in New Zealand • Volpara signs a breast cancer screening software supply agreement with Intermountain Health in the U.S. • Joint development of AI-powered pathology solutions with AstraZeneca • Volpara signs a supply contract with the U.S. Defense Health Agency (DHA) for breast cancer screening software
2025	• MFDS Clearance - **Lunit INSIGHT DBT** • Volpara signs a supply contract with SimonMed Imaging for breast cancer screening software • CE marked in Europe - **Lunit INSIGHT CXR4** • Acquired key technology assets from U.S.-based Prognosia • U.S. FDA Clearance Submitted - **Lunit INSIGHT Risk** • Renamed Volpara Health Technologies Ltd. and Volpara Health Inc. to Lunit International Ltd. and Lunit Americas Inc.
2026	• Won 'Malta National Breast Cancer Screening Program' Contract • Partnered with Leica Biosystems and Indica Labs for U.S. Distribution of Lunit SCOPE • Partnered with Lexington Clinic to Deliver an Integrated Breast Cancer Diagnostic Solution

II. Board of Directors

To respond swiftly to the rapidly evolving medical AI industry and fast-changing global business environment, Lunit has established a Board composed of leading experts in biotechnology, AI, finance and accounting, Capital Market, law and policy. The Board consists of six directors: two inside directors, two independent directors and two non-executive directors, and Lunit pursues diversity in Board composition regardless of age, gender or nationality. As its highest decision-making body, the Board reviews and approves key corporate matters. As of the first half of 2026, Lunit held 5 Board meetings and conducted in-depth discussions on 23 items, including 15 resolutions and 8 reporting/discussion items.

Lunit operates the Audit Committee, Compensation Committee, and Independent Director Nomination Committee under the Board to strengthen Board expertise and decision-making independence. Lunit's Audit Committee serves as a key oversight body that supervises management in compliance with applicable laws and regulations while enhancing accounting and financial transparency. In addition, Lunit operates the Compensation Committee to maximize objectivity and transparency in determining executive and director compensation. On April 30, 2026, Lunit also established the Independent Director Nomination Committee, which is responsible for assessing the qualifications and competencies of director candidates and recommending suitable candidates to the Board of Directors.

Board of Directors

Seungwook Paek (Chair)
Beomseok Suh
Wonbok Lee
Zeongwon Kim
Garheng Kong
Joonpyo Lee

Audit Committee	Compensation Committee	Independent Director Nomination Committee
Zeongwon Kim (Chair)	**Garheng Kong (Chair)**	**Wonbok Lee (Chair)**
Wonbok Lee	Zeongwon Kim	Seungwook Paek
Joonpyo Lee		Zeongwon Kim

III. Business Report

1. Overview of Company

A. Objectives of the Company

1. Development of technologies and services utilizing visual data (images/videos)
2. Development, manufacture, distribution, advisory, maintenance and services of image-based product search solutions
3. Development, manufacture, distribution, advisory and maintenance of software
4. Data processing and database business
5. Manufacture, sale, import, lease and repair of medical devices
6. Other professional, scientific and technical service businesses
7. Medical and pharmaceutical research and development business
8. Information service business (information processing and provision technologies)
9. Mobile business
10. Content development business
11. Sale of hardware and peripheral devices
12. Technology services business
13. Other insurance and pension related services
14. E-commerce related services and distribution
15. Real estate development, supply and leasing business
16. Food and beverage sales and cafe operation
17. Any e-commerce and mail-order sales related to the above businesses
18. Wholesale, retail, import/export, and agency services related to the above businesses
19. Any and all incidental businesses related to the above

B. Details of Major Businesses

- The Company has developed and commercialized deep learning-based AI solutions that overcome the limitations of human vision in medical image interpretation, thereby strengthening its competitiveness in the medical AI market. The Company is also developing AI imaging biomarker solutions that analyze pathology images to identify novel imaging biomarkers beyond the limits of human visual cognition and pattern recognition and expand the application of AI in healthcare.

- The Company's principal products and services include Lunit INSIGHT, an AI-powered medical image interpretation solution, and breast cancer screening software in the Cancer Screening segment, and Lunit SCOPE, an AI imaging biomarker solution for the Oncology segment. Based on their functions, the product portfolio is categorized as follows. In the Cancer Screening segment, the Company offers: (1) solutions that assist medical image interpretation for early cancer detection; (2) solutions that identify imaging biomarkers based on medical images to predict cancer risk; and (3) solutions that provide breast density analysis and breast cancer risk assessment based on mammography images. In the Oncology segment, the Company offers: (1) solutions that assist in pathology slide interpretation to quantify biomarker expression levels; and (2) solutions that identify novel imaging biomarkers to predict treatment responses to immuno-oncology therapies and other treatments.

- The Company has established global sales and R&D networks across major international markets. For the first half of 2026, on a consolidated basis, the Company recorded revenue of KRW 45,766 million, of which 95% was derived from oversea markets. For Lunit INSIGHT, the Company has expanded its global sales network through partnerships with leading medical imaging companies, including GE Healthcare, Philips, Fujifilm, and Hologic, while also strengthening direct sales operations through subsidiaries in key markets such as the U.S. and Japan. In May 2024, the Company completed the acquisition of New Zealand-based Lunit International Ltd. (formerly Volpara Health Technologies, Ltd.), establishing a strong foundation for expansion into the U.S. market. Lunit International Ltd. provides breast cancer-related software for cancer risk assessment and breast density analysis and has an extensive global network used by more than 9,500 healthcare professionals across over 3,600 institutions worldwide. For Lunit SCOPE, the Company is expanding its research-use-only (RUO) business with pharmaceutical companies, clinical research organizations, diagnostic testing service providers, and Guardant Health, a global leader in liquid biopsy. Through these RUO collaborations, the Company aims to generate clinical evidence and strengthen its market presence, with the long-term goal of obtaining companion diagnostics (CDx) approvals to expand into the clinical market.

C. Headquarters and Branch Offices

Category	Country	Company Name	Main Business
Headquarters	Republic of Korea	Lunit Inc.	Development and supply of medical AI software
Subsidiary	United States	Lunit USA, Inc.	
	China	Lunit China Co., Ltd.	
	Netherlands	Lunit Europe Holdings B.V.	
	Japan	Lunit Japan Co., Ltd.	
	New Zealand	Lunit International Ltd.	
Sub-subsidiary	Germany	Lunit Europe GmbH[1)]	
	New Zealand	Lunit Finance NZ Ltd.[2)]	
	Canada	Lunit Canada, Inc.[2)]	
	Denmark	Lunit Denmark ApS[2)]	
	United States	Lunit Americas, Inc.[2)]	
	Australia	Lunit Australia Pty Ltd.[2)]	
	United Kingdom	Lunit UK Ltd.[2)]	

1) A wholly owned subsidiary of Lunit Europe Holdings B.V.
2) A wholly owned subsidiary of Lunit International Ltd.

D. Employees

(Unit: persons)

R&D	Sales & Marketing	Admin	Total
246	139	90	475

1) Based on consolidated headcount, including subsidiaries.
2) Excluding registered executives and outside directors.

E. Organization Chart



1) Based on the headquarters only.

F. Stock Information

1. Class and number of issued shares

(Unit: shares, KRW thousand, %)

Class	No. of Shares	Amount	Composition	Notes
Common Stock	74,458,180	37,229,090	100.00	-
Total	74,458,180	37,229,090	100.00	-

2. Changes in Capital Stock

(Unit: shares, KRW thousand)

Date (yyyy.mm.dd.)	Class of Shares	No. of Shares	Amount of Capital Increase (Reduction)	Capital Stock After Increase (Reduction)	Capital Increase (Reduction) Description
2022.07.16.	Common Stock	1,215,800	607,900	6,078,800	Capital Increase (Public Offering, IPO)
	Common Stock	33,333	16,667		Capital Increase (Third-Party Allotment to Underwriter)
2022.08.16.	Common Stock	65,879	32,940	6,111,739	Exercise of Stock Options
2022.10.17.	Common Stock	4,150	2,075	6,113,814	Exercise of Stock Options
2023.01.13.	Common Stock	27,557	13,779	6,127,593	Exercise of Stock Options
2023.04.14.	Common Stock	85,469	42,735	6,170,327	Exercise of Stock Options
2023.07.14.	Common Stock	40,350	20,175	6,190,502	Exercise of Stock Options
2023.11.10.	Common Stock	1,857,150	928,575	7,119,077	Capital Increase
2023.11.10.	Common Stock	14,238,154	7,119,077	14,238,154	Bonus Issue (1 share issued for each existing share)
2023.12.21.	Common Stock	225,969	112,985	14,351,139	Exercise of Stock Options
2024.01.19.	Common Stock	57,533	28,767	14,379,905	Exercise of Stock Options
2024.04.19.	Common Stock	70,820	35,410	14,415,315	Exercise of Stock Options
2024.07.16.	Common Stock	42,522	21,261	14,436,576	Exercise of Stock Options
2024.10.18.	Common Stock	69,748	34,874	14,471,450	Exercise of Stock Options
2025.01.21.	Common Stock	52,340	26,170	14,497,620	Exercise of Stock Options

2025.04.22.	Common Stock	154,678	77,339	14,574,959	Exercise of Stock Options
2025.07.21.	Common Stock	54,672	27,336	14,602,295	Exercise of Stock Options
2025.10.20.	Common Stock	52,156	26,078	14,628,373	Exercise of Stock Options
2026.01.16.	Common Stock	27,756	13,878	14,642,251	Exercise of Stock Options
2026.05.01.	Common Stock	7,906,816	3,953,408	18,595,659	Capital Increase
2026.05.04.	Common Stock	37,191,318	18,595,659	37,191,318	Bonus Issue (1 share issued for each existing share)
2026.05.06.	Common Stock	75,544	37,772	37,229,090	Exercise of Stock Options

1) Represents changes in capital stock over the past five years.
2) Converted into common stock upon the exercise of conversion rights.

3. Stock Affairs

<table>
<tr><td>Fiscal Year-End</td><td colspan="3">December 31</td></tr>
<tr><td>Record Date</td><td>Last day of each fiscal year</td><td>Annual General Meeting of Shareholders</td><td>Within 3 months after the end of each fiscal year</td></tr>
<tr><td>Public Notice Method</td><td colspan="3">Company website (www.lunit.io) or The Korea Economic Daily</td></tr>
<tr><td>Type of Share Certificate</td><td colspan="3">-1)</td></tr>
<tr><td>Transfer Agent</td><td colspan="3">Korea Securities Depository (T. +82-51-519-1500)</td></tr>
</table>

1) Pursuant to the “Act on Electronic Registration of Stocks, Bonds, etc.”, the rights required to be indicated on share certificates and share warrant certificates were mandatorily registered electronically on January 4, 2022. Accordingly, the “Type of Share Certificate” is not stated.

4. Bonds Information

- The Company issued two rounds of privately placed unsecured convertible bonds in May 2024. The first tranche was issued on May 3, 2024, and the second tranche was issued on May 31, 2024. For further details, please refer to the “Results of Securities Issuance (Voluntary Disclosure)” disclosures dated May 3, 2024 and May 31, 2024.

2. Sales Progress and Performance

A. Overview of Sales

1. Cancer Screening (AI-Assisted Medical Imaging Analysis)

- Lunit INSIGHT CXR and Lunit INSIGHT MMG are AI-assisted imaging analysis solutions for the Cancer Screening segment. Lunit INSIGHT CXR detects more than 10 types of abnormalities in chest X-ray images, while Lunit INSIGHT MMG detects suspicious breast cancer lesions and classifies breast density in mammography images. Lunit INSIGHT CXR received regulatory approval from the Korean Ministry of Food and Drug Safety (MFDS) in August 2018, while Lunit INSIGHT CXR Triage, designed to identify urgent conditions such as pneumothorax and pleural effusion, received U.S. Food and Drug Administration (FDA) clearance in November 2021. In addition, in November 2022, both Lunit INSIGHT CXR and Lunit INSIGHT MMG obtained CE certification under the EU Medical Device Regulation (MDR), enabling the Company to proactively respond to evolving regulatory requirements in the European market. The Company also launched Lunit INSIGHT DBT, which assists physicians by detecting suspicious breast cancer lesions in digital breast tomosynthesis images. Lunit INSIGHT DBT obtained CE certification in Europe in February 2023, U.S. FDA clearance in November 2023, and Korean MFDS approval in April 2025, supporting the Company's global market expansion.

- The business model of Lunit INSIGHT consists of: (1) integration with Picture Archiving and Communication Systems (PACS) ("Platform model"); (2) integration with or embedding into medical imaging equipment ("Modality model"); and (3) subscription-based Software-as-a-Service ("SaaS") offerings. Under the Platform model, the Company charges a fixed fee per image analyzed and bills customers through monthly or quarterly subscriptions. Under the Modality model, the Company charges a fixed fee per imaging device sold and additionally collects annual maintenance fees. Under the SaaS model, customers enter into long-term usage agreements and prepay annual subscription fees.

- To support these business models, the Company collaborates with global manufacturers in the X-ray imaging equipment, mammography equipment, and PACS markets, enabling bundled offerings and joint sales activities. The Company has entered into distribution and sales agreements with global medical device companies such as GE Healthcare, Philips, Fujifilm, and Hologic, as well as healthcare IT companies including Agfa, Sectra, and Emergent Connect. As these partners collectively account for nearly 50% of their respective markets, the Company expects to further accelerate market penetration and business expansion. As of the first half of 2026, more than 8,000 medical institutions worldwide had adopted Lunit INSIGHT.

- In addition, leveraging the U.S. sales channels and other networks of Lunit International Ltd., which the Company acquired in May 2024, the Company is expanding its direct sales operations in addition to partner-based sales. Lunit International Ltd. has established direct sales channels in key markets including the U.S., Canada, Australia, and New Zealand, allowing the Company to build closer relationships with customers.

2. Oncology (Cancer Treatment Response Prediction)

- Lunit SCOPE, the Company's AI imaging biomarker solution for the Oncology segment, is currently used to predict responses to immuno-oncology therapies by quantifying the expression levels of biomarkers such as PD-L1 and TIL. The Company has completed research and development for solutions capable of predicting treatment responses to immuno-oncology therapies across lung cancer and 15 additional cancer types and generated its first RUO revenue in the third quarter of 2023. The Company is currently entering into research agreements with multiple global pharmaceutical companies and aims to obtain clinical approval for use as a companion diagnostic

(CDx) biomarker for cancer therapies.

- Lunit SCOPE has also conducted collaborative research with leading hospitals and research institutions in Korea and has demonstrated its technological capabilities through various clinical publications. In June 2021, the Company entered into a partnership with Guardant Health, a global leader in liquid biopsy, enabling the Company to leverage an extensive clinical network for developing and validating novel biomarkers for use in real-world clinical settings.
- Through its collaboration with Guardant Health, the Company recognized milestone revenue from research and development activities in 2023 and successfully completed the joint development and launch of collaborative products. In addition, the Company continues to expand its research beyond immuno-oncology therapies into targeted therapies and antibody-drug conjugates (ADCs).

B. Sales Performance

(Unit: KRW million)

Category		1H 2026		2025 (13th)		2024 (12th)	
		Amount	%	Amount	%	Amount	%
Cancer Screening	Software	40,806	89.16	67,465	81.16	46,212	85.29
	Others	2,031	4.44	5,290	6.36	3,962	7.31
Oncology	Services	2,815	6.15	10,101	12.15	3,429	6.33
	Others	114	0.25	273	0.33	576	1.06
Others		-	-	-	-	1	0.01
Total		45,766	100.00	83,129	100.00	54,180	100.00

(Unit: KRW million)

Category	1H 2026	2025 (13th)
Domestic Sales	2,333	6,330
Overseas Sales	43,433	76,799
Total	45,766	83,129

(Unit: KRW million)

Category	1H 2026	2025 (13th)
Company A [1)]	5,615	10,514
Total	5,615	10,514

1) Represents more than 10% of consolidated revenue.

3. Status of Parent Company and Subsidiaries

A. Parent Company

- None

B. Subsidiaries

(Unit: shares, %)

Company Name	Subsidiaries		Relation with Company		
	Capital	Main Business	No. of Shares	Ownership (%)	Transaction Relationship
Lunit USA, Inc.	USD 33,600	Development and supply of medical AI software	336,000	100.00	-
Lunit China Co., Ltd.	CNY 1,499,916		-	100.00	-
Lunit Europe Holdings B.V.	EUR 1,360,000		1,360,000	100.00	-
Lunit Japan Co., Ltd.	JPY 130,000,000		13,000	100.00	-
Lunit International Ltd.	NZD 198,787,972		260,956,512	100.00	-
Lunit Europe GmbH[1)]	EUR 1,060,000		1,060,000	100.00	-
Lunit Finance NZ Ltd.[2)]	NZD 357,000		1,000	100.00	-
Lunit Canada, Inc.[2)]	CAD 100,000		1,000	100.00	-
Lunit Denmark ApS[2)]	DKK 20,000		20,000	100.00	-
Lunit Americas, Inc.[2)]	USD 28,910,153		10,000,000	100.00	-
Lunit Australia Pty Ltd.[2)]	AUD 10,000		1,000,000	100.00	-
Lunit UK Ltd.[2)]	GBP 100		10,000	100.00	-

1) A wholly owned subsidiary of Lunit Europe Holdings B.V.
2) A wholly owned subsidiary of Lunit International Ltd.

C. Executives' Concurrent Positions in Subsidiaries

Executive		Concurrent Position (Subsidiaries)	
Name	**Position**	**Company Name**	**Position**
Beomseok Suh	CEO (Registered Executive)	Lunit USA, Inc.	CEO (Registered Executive)
		Lunit China Co., Ltd	CEO (Registered Executive)
		Lunit Europe Holdings B.V.	CEO (Registered Executive)
		Lunit Japan Co., Ltd.	CEO (Registered Executive)
		Lunit International Ltd.	Director
		Lunit Finance NZ Ltd.	Director
		Lunit Americas, Inc.	Director
Seungwook Paek	Inside Director (Registered Executive)	Lunit USA, Inc.	Director
		Lunit International Ltd.	Director
		Lunit Finance NZ Ltd.	Director
		Lunit Americas, Inc.	Director
Hyeonseong Park	Inside Director (Non-registered Executive)	Lunit USA, Inc.	Executive Officer

4. Operation Results & Financial Condition for Past 3 Years

A. Summary Consolidated Statements of Financial Position: 2024–1H 2026

- The summary consolidated statements of financial position as of June 30, 2026, December 31, 2025, and December 31, 2024 have been prepared in accordance with Korean International Financial Reporting Standards (K-IFRS). The financial information as of June 30, 2026 is only reviewed, whereas the financial information as of December 31, 2025 and December 31, 2024 has been derived from audited consolidated financial statements.

(Unit: KRW)

Account	1H 2026	2025 (13th)	2024 (12th)
1. Current assets	217,163,344,398	55,619,662,929	111,882,055,343
2. Non-current assets	328,107,313,896	314,292,034,266	321,032,423,264
Total assets	545,270,658,294	369,911,697,195	432,914,478,607
1. Current liabilities	196,794,572,562	212,212,100,968	252,412,814,540
2. Non-current liabilities	16,834,466,525	20,266,695,958	17,766,852,239
Total liabilities	213,629,039,087	232,478,796,926	270,179,666,779
[Equity attributable to owners of parent]			
1. Issued capital	37,229,090,000	14,628,373,000	14,471,450,000
2. Capital surplus	746,773,512,890	549,031,241,883	526,645,689,887
3. Accumulated other comprehensive income	15,127,637,690	(121,277,833)	(278,027,018)
4. Retained earnings (deficit)	(467,488,621,373)	(426,105,436,781)	(378,104,301,041)
[Non-controlling interests]	-	-	-
Total equity	331,641,619,207	137,432,900,269	162,734,811,828

B. Summary Separate Statements of Financial Position: 2024–1H 2026

- The summary separate statements of financial position as of June 30, 2026, December 31, 2025, and December 31, 2024 have been prepared in accordance with Korean International Financial Reporting Standards (K-IFRS). The financial information as of June 30, 2026 is only reviewed, whereas the financial information as of December 31, 2025 and December 31, 2024 has been derived from audited separate financial statements.

(Unit: KRW)

Account	1H 2026	2025 (13th)	2024 (12th)
1. Current assets	174,660,389,432	30,025,069,346	85,735,835,728
2. Non-current assets	333,605,543,013	331,028,640,842	329,030,967,997
Total assets	508,265,932,445	361,053,710,188	414,766,803,725
1. Current liabilities	160,819,612,915	185,684,151,729	222,982,138,567
2. Non-current liabilities	14,705,976,723	18,637,784,073	16,773,855,188
Total liabilities	175,525,589,638	204,321,935,802	239,755,993,755
1. Issued capital	37,229,090,000	14,628,373,000	14,471,450,000
2. Capital surplus	746,773,512,890	549,031,241,883	526,645,689,887
3. Retained earnings (deficit)	(451,262,260,083)	(406,927,840,497)	(366,106,329,917)
Total equity	332,740,342,807	156,731,774,386	175,010,809,970

C. Summary Consolidated Statements of Profit or Loss: 2024–1H 2026

- The summary consolidated statements of profit or loss for the six-month period ended June 30, 2026 and for the years ended December 31, 2025 and 2024 have been prepared in accordance with Korean International Financial Reporting Standards (K-IFRS). The financial information for the six-month period ended June 30, 2026 is only reviewed, whereas the financial information for the years ended December 31, 2025 and December 31, 2024 has been derived from audited consolidated financial statements.

(Unit: KRW)

Account	1H 2026	2025 (13th)	2024 (12th)
Revenue	45,766,053,690	83,129,295,404	54,179,663,335
Operating income(loss)	(28,962,075,568)	(83,103,910,311)	(67,947,200,428)
Profit (loss)	(41,366,751,080)	(47,389,679,756)	(82,695,495,892)
Other comprehensive income	15,232,482,011	(454,706,799)	(927,412,580)
Comprehensive income(loss)	(26,134,269,069)	(47,844,386,555)	(83,622,908,472)
Basic earnings (loss) per share	(325)	(1,627)	(2,867)
Diluted earnings (loss) per share	(325)	(2,825)	(2,867)

D. Summary Separate Statements of Profit or Loss: 2024–1H 2026

- The summary separate statements of profit or loss for the six-month period ended June 30, 2026 and for the years ended December 31, 2025 and 2024 have been prepared in accordance with Korean International Financial Reporting Standards (K-IFRS). The financial information for the six-month period ended June 30, 2026 is only reviewed, whereas the financial information for the years ended December 31, 2025 and December 31, 2024 has been derived from audited separate financial statements.

(Unit: KRW)

Account	1H 2026	2025 (13th)	2024 (12th)
Revenue	14,535,592,471	32,822,258,104	25,718,636,502
Operating income(loss)	(31,945,137,996)	(76,556,335,514)	(58,981,984,803)
Profit (loss)	(44,317,986,074)	(40,210,054,596)	(74,043,019,945)
Other comprehensive income	(16,433,512)	(611,455,984)	(467,946,575)
Comprehensive income(loss)	(44,334,419,586)	(40,821,510,580)	(74,510,966,520)
Basic earnings (loss) per share	(340)	(1,380)	(2,567)
Diluted earnings (loss) per share	(340)	(2,604)	(2,567)

5. Tasks Facing the Company

A. Cash Flow Management

- For the first half of 2026, the Company recorded consolidated revenue of KRW 45.8 billion, while operating loss amounted to KRW 29 billion.
- As the Company's operating cash flow is not yet sufficient to cover operating expenses, the Company has relied on external financing to fund a substantial portion of its operating activities. In December 2023, the Company completed a shareholder rights offering, and in May 2024, the Company issued privately placed convertible bonds to secure operating funds and financing for equity investments.
- Subsequently, the Company completed its shareholder rights offering at the end of April 2026, securing additional cash for debt repayment and operations, and continues to focus on prudent cash flow management.
- The Company is managing operating expenses to support continued business expansion until revenue becomes more stable. In particular, as uncertainties in the macroeconomic environment are expected to persist, management of cash expenditures and cash balances has become increasingly important.

B. Business Model Diversification

- The AI-based software developed by the Company represents a new category of AI-based medical software. As a result, the Company is able to pursue a variety of business models, and establishing appropriate business models is considered a key factor for mid- to long-term growth.
- For Lunit INSIGHT, the Company has established business models based on PACS integration ("Platform model") and device integration ("Modality model"), while also pursuing additional business opportunities such as B2C services, collaborations with insurance companies, and AI-generated reports. In addition, the Company is expanding into AI-based cancer risk prediction using medical imaging and is diversifying its business models by expanding the applicability of medical AI solutions through the development of foundation models utilizing various medical datasets.
- For Lunit SCOPE, the Company is developing business models through collaborations with global pharmaceutical companies, participation in clinical trials, and partnerships with insurance companies. In the mid to long term, the Company aims to expand the clinical application of Lunit SCOPE through regulatory approvals.

6. Directors and Auditors

Classification	Name	Position	Responsibilities	Relationship with the Company
Full-time / Registered	Beomseok Suh	CEO (Inside Director)	Chief Executive Officer	-
	Seungwook Paek	Inside Director	Executive Chairman	Largest Shareholder
Non-full-time / Registered	Garheng Kong	Non-executive Director	Management Advisory Compensation Committee Member	-
	Wonbok Lee	Independent Director	Management Advisory Audit Committee Member	-
	Zeongwon Kim	Independent Director	Management Advisory Audit Committee Member Compensation Committee Member	-
	Joonpyo Lee	Non-executive Director	Management Advisory Audit Committee Member	-
Full-time / Unregistered	Jungin Lee	Director	Dept. Head of Infrastructure	-
	Donggeun Yoo	Director	Chief AI Officer	-
	Sunggyun Park	Director	Chief Operating and Regulation Officer	-
	Kyunghyun Paeng	Director	Chief Product Officer	-
	Kihwan Kim	Director	Head of Cancer Screening Group	-
	Hyeonseong Park	Director	Chief Financial Officer	-
	Ken Nesmith	Director	Head of Oncology Group	-
	Richard Yoo	Director	Chief Technology Officer	-

7. Major Shareholders

(Unit: shares, %)

Name of shareholder	No. of Shares	Ownership (%)	Transaction Relationship with the Company	Notes
Seungwook Paek	4,113,852	5.53	Largest Shareholder	-

8. Ownership Status of Affiliates and Subsidiaries

(Unit: shares, %)

Investee	Investor	Investor's investments to Investee		Investee's investments to the Company	
		No. of shares owned	Ownership (%)	No. of shares owned	Ownership (%)
Lunit USA, Inc.	Lunit Inc.	336,000	100.00	-	-
Lunit China Co., Ltd.	Lunit Inc.	-	100.00	-	-
Lunit Europe Holdings B.V.	Lunit Inc.	1,360,000	100.00	-	-
Lunit Japan Co., Ltd.	Lunit Inc.	13,000	100.00	-	-
Lunit International Ltd.	Lunit Inc.	260,956,512	100.00	-	-
Lunit Europe GmbH	Lunit Europe Holdings B.V.	1,060,000	100.00	-	-
Lunit Finance NZ Ltd.	Lunit International Ltd.	1,000	100.00	-	-

Lunit Canada, Inc.	Lunit International Ltd.	1,000	100.00	-	-
Lunit Denmark ApS	Lunit International Ltd.	20,000	100.00	-	-
Lunit Americas, Inc.	Lunit International Ltd.	10,000,000	100.00	-	-
Lunit Australia Pty Ltd.	Lunit International Ltd.	1,000,000	100.00	-	-
Lunit UK Ltd.	Lunit International Ltd.	10,000	100.00	-	-

9. Major Creditors, Etc.

- The Company's major creditors include the underwriting institutions of the 1st and 2nd convertible bonds issued by the Company in May 2024. For further details, please refer to the "Report on Securities Issuance Results (Voluntary Disclosure) (1st CB)" and "Report on Securities Issuance Results (Voluntary Disclosure) (2nd CB)" disclosed on May 3, 2024 and May 31, 2024, respectively.

10. Events after the Reporting Period

1. Early Redemption of Convertible Bonds

- The holders of the convertible bonds issued by the Company are granted a put option that allows them to request early redemption of all or a portion of the bonds they hold prior to maturity. Such right may be exercised every three months, commencing on the second anniversary of the issuance date, at an amount equal to the principal plus accrued interest calculated at a compound annual rate of 8.0%.
- Subsequent to the reporting period, the Company received notice from the holder of the 1st convertible bonds that it had exercised its put option for early redemption of bonds with an aggregate principal amount of KRW 44,695 million. Accordingly, the Company paid a total early redemption amount of KRW 52,364 million, including the applicable early redemption yield, on August 3, 2026.

11. Other Important Matters Related to Operations

- None

IV. Financial Statements

1. Consolidated Statements of Financial Position

(Unit: KRW)

	1H 2026	2025 (13th)
Assets		
Current assets	217,163,344,398	55,619,662,929
Cash and cash equivalents	154,530,214,952	14,110,597,196
Current trade receivables	22,374,323,146	21,802,146,800
Other current financial assets	1,808,129,821	802,588,311
Current financial assets at fair value through profit or loss	27,394,274,258	6,500,467,936
Current derivative financial assets	0	2,254,733,267
Current contract assets	5,986,400,971	4,566,674,908
Other current assets	4,671,407,120	4,639,050,904
Current inventories	112,602,627	124,283,943
Current tax assets	285,991,503	819,119,664
Non-current assets	328,107,313,896	314,292,034,266
Non-current trade receivables	5,545,542,005	5,714,030,829
Property, plant and equipment	5,401,374,659	6,238,124,127
Right-of-use assets	14,180,392,875	15,361,698,758
Intangible assets and goodwill	293,543,825,917	278,704,461,701
Non-current financial assets at fair value through profit or loss	1,380,092,823	1,380,092,823
Other non-current financial assets	1,764,305,951	1,735,411,699
Other non-current assets	5,291,943,282	4,857,271,561
Non-current net defined benefit asset	676,536,310	0
Deferred tax assets	323,300,074	300,942,768
Total assets	545,270,658,294	369,911,697,195
Liabilities		
Current liabilities	196,794,572,562	212,212,100,968
Current trade payables	30,447,000	6,183,388
Current loans received and current portion of non-current loans received	12,000,000,000	18,910,194,575
Other current financial liabilities	7,983,826,196	11,632,874,259
Current derivative financial liabilities	56,269,596,441	72,325,644,459
Current portion of convertible bonds	79,775,959,675	74,459,326,891
Other current liabilities	40,725,925,004	34,872,157,814
Current tax liabilities	5,742,288	5,719,582
Other current provisions	3,075,958	0
Non-current liabilities	16,834,466,525	20,266,695,958
Non-current net defined benefit liability	0	3,317,030,285
Other long-term employee benefit liabilities	488,919,401	505,918,631
Other non-current financial liabilities	13,929,561,152	14,708,730,151
Other non-current liabilities	1,391,129,225	1,117,898,994
Other non-current provisions	573,487,550	568,327,916
Deferred tax liabilities	451,369,197	48,789,981
Total liabilities	213,629,039,087	232,478,796,926
Equity		
Equity attributable to owners of parent	331,641,619,207	137,432,900,269
Issued capital	37,229,090,000	14,628,373,000
Capital surplus	746,773,512,890	549,031,241,883
Accumulated other comprehensive income	15,127,637,690	-121,277,833
Retained earnings (deficit)	-467,488,621,373	-426,105,436,781
Non-controlling interests	0	0
Total equity	331,641,619,207	137,432,900,269
Total equity and liabilities	545,270,658,294	369,911,697,195

2. Consolidated Statements of Comprehensive Income

(Unit: KRW)

	1H 2026	1H 2025
Revenue	45,766,053,690	37,077,150,438
Operating expense	74,728,129,258	78,988,189,939
Operating income(loss)	-28,962,075,568	-41,911,039,501
Finance income	14,840,701,257	28,142,621,183
Finance costs	26,329,699,067	19,135,071,379
Other gains	37,963,558	96,228,757
Other losses	62,404,626	36,139,746
Profit (loss) before tax	-40,475,514,446	-32,843,400,686
Tax expense (income)	891,236,634	224,623,493
Profit (loss)	-41,366,751,080	-33,068,024,179
Other comprehensive income	15,232,482,011	933,555,726
Other comprehensive income that will be reclassified to profit or loss, net of tax	15,248,915,523	968,878,240
Gains (losses) on exchange differences on translation of foreign operations, net of tax	15,248,915,523	968,878,240
Other comprehensive income that will not be reclassified to profit or loss, net of tax	-16,433,512	-35,322,514
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-16,433,512	-35,322,514
Comprehensive income	-26,134,269,069	-32,134,468,453
Profit (loss), attributable to		
Profit (loss), attributable to owners of parent	-41,366,751,080	-33,068,024,179
Profit (loss), attributable to non-controlling interests	0	0
Comprehensive income attributable to		
Comprehensive income, attributable to owners of parent	-26,134,269,069	-32,134,468,453
Comprehensive income, attributable to non-controlling interests	0	0
Earnings per share		
Basic earnings (loss) per share	-615	-569
Diluted earnings (loss) per share	-615	-664

3. Consolidated Statements of Changes in Equity

(Unit: KRW)

	Equity attributable to owners of parent				
	Issued capital	Elements of other stockholders equity	Other Comprehensive income/loss accumulated amount	Retained earnings	
1H 2026					
Statement of changes in equity					
Equity at beginning of period	14,628,373,000	549,031,241,883	-121,277,833	-426,105,436,781	137,432,900,269
Increase (decrease) through transactions with owners, equity	22,600,717,000	197,742,271,007	0	0	220,342,988,007
Increase (decrease) through exercise of warrants, equity	51,650,000	881,877,670	0	0	933,527,670
Increase (decrease) through share-based payment transactions, equity	0	10,278,882,982	0	0	10,278,882,982
Issue of equity	3,953,408,000	205,177,169,355	0	0	209,130,577,355
Bonus issue	18,595,659,000	-18,595,659,000	0	0	0
Comprehensive income	0	0	15,248,915,523	-41,383,184,592	-26,134,269,069
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	0	0	0	-16,433,512	-16,433,512
Gains (losses) on exchange differences on translation of foreign operations, net of tax	0	0	15,248,915,523	0	15,248,915,523
Profit (loss)	0	0	0	-41,366,751,080	-41,366,751,080
Equity at end of period	37,229,090,000	746,773,512,890	15,127,637,690	-467,488,621,373	331,641,619,207
1H 2025					
Statement of changes in equity					
Equity at beginning of period	14,471,450,000	526,645,689,887	-278,027,018	-378,104,301,041	162,734,811,828
Increase (decrease) through transactions with owners, equity	103,509,000	11,159,685,550	0	0	11,263,194,550
Increase (decrease) through exercise of warrants, equity	103,509,000	2,182,575,380	0	0	2,286,084,380
Increase (decrease) through share-based payment transactions, equity	0	8,977,110,170	0	0	8,977,110,170
Issue of equity	0	0	0	0	0
Bonus issue	0	0	0	0	0
Comprehensive income	0	0	968,878,240	-33,103,346,693	-32,134,468,453
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	0	0	0	-35,322,514	-35,322,514
Gains (losses) on exchange differences on translation of foreign operations, net of tax	0	0	968,878,240	0	968,878,240
Profit (loss)	0	0	0	-33,068,024,179	-33,068,024,179
Equity at end of period	14,574,959,000	537,805,375,437	690,851,222	-411,207,647,734	141,863,537,925

4. Consolidated Statements of Cash Flow

(Unit: KRW)

	1H 2026	1H 2025
Cash flows from (used in) operating activities	-21,827,905,768	-25,182,369,722
Cash flows from (used in) operations	-20,085,523,818	-25,141,527,962
Interest received	746,790,431	607,926,645
Interest paid	-2,478,845,696	-948,424,307
Income taxes refund (paid)	-10,326,685	299,655,902
Cash flows from (used in) investing activities	-21,257,879,325	-4,574,783,749
Inflows of cash from investing activities	11,665,538,803	12,435,896,761
Proceeds from sales of short term Financial Instruments	0	5,000,000,000
Proceeds from sales of property, plant and equipment	78,504,137	37,114,525
Decrease in other guarantee deposit	100,507,923	20,178,301
Proceeds from sales of fair value financial asset	9,369,422,485	7,378,603,935
Increase in deposits received	2,117,104,258	0
Outflows of cash from investing activities	-32,923,418,128	-17,010,680,510
Purchase of property, plant and equipment	-330,643,081	-502,389,911
Purchase of intangible assets	-2,149,527,152	-7,972,229,800
Cash advances and loans made to other parties	-331,622,708	-390,460,799
Purchase of financial assets measured at fair value through profit or loss	-30,111,566,884	-8,145,600,000
Increase in guarantee deposits	-58,303	0
Cash flows from (used in) financing activities	181,986,114,503	19,994,010,352
Inflows of cash from financing activities	240,064,105,025	21,171,915,077
Proceeds from exercise of share options	933,527,670	2,286,084,380
Proceeds from short term borrowings	30,000,000,000	18,885,830,697
Proceeds from issue of ordinary shares	209,130,577,355	0
Outflows of cash from financing activities	-58,077,990,522	-1,177,904,725
Payments of finance lease liabilities	-1,332,098,300	-1,177,904,725
Repayments of short term borrowings	-37,232,745,715	0
Repayments of convertible bonds	-19,513,146,507	0
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	138,900,329,410	-9,763,143,119
Cash and cash equivalents at beginning of period	14,110,597,196	52,369,332,882
Effect of exchange rate changes on cash and cash equivalents	1,519,288,346	-899,362,369
Cash and cash equivalents at end of period	154,530,214,952	41,706,827,394

5. Separate Statements of Financial Position

(Unit: KRW)

	1H 2026	2025 (13th)
Assets		
Current assets	174,660,389,432	30,025,069,346
Cash and cash equivalents	133,285,659,307	4,417,207,942
Current trade receivables	10,022,761,846	13,965,899,808
Other current financial assets	2,260,623,487	903,528,708
Current financial assets at fair value through profit or loss	27,394,274,258	6,500,467,936
Current derivative financial assets	0	2,254,733,267
Other current assets	1,541,148,959	1,694,367,521
Current inventories	112,602,627	124,283,943
Current tax assets	43,318,948	164,580,221
Non-current assets	333,605,543,013	331,028,640,842
Non-current trade receivables	5,545,542,005	5,714,030,829
Investments in subsidiaries reported in separate financial statements	294,501,269,512	291,554,845,651
Property, plant and equipment	4,669,178,998	5,706,086,821
Right-of-use assets	13,246,292,261	14,429,153,822
Intangible assets other than goodwill	9,978,829,754	8,787,576,231
Non-current financial assets at fair value through profit or loss	1,380,092,823	1,380,092,823
Other non-current financial assets	1,754,036,938	1,709,484,871
Other non-current assets	1,853,764,412	1,747,369,794
Non-current net defined benefit asset	676,536,310	0
Total assets	508,265,932,445	361,053,710,188
Liabilities		
Current liabilities	160,819,612,915	185,684,151,729
Current trade payables	30,447,000	6,183,388
Current loans received and current portion of non-current loans received	12,000,000,000	12,000,000,000
Other current financial liabilities	9,584,137,732	23,631,369,532
Current derivative financial liabilities	56,269,596,441	72,325,644,459
Current portion of convertible bonds	79,775,959,675	74,459,326,891
Other current liabilities	3,156,396,109	3,261,627,459
Other current provisions	3,075,958	0
Non-current liabilities	14,705,976,723	18,637,784,073
Non-current net defined benefit liability	0	3,317,030,285
Other long-term employee benefit liabilities	488,919,401	505,918,631
Other non-current financial liabilities	12,800,547,598	13,746,290,563
Other non-current liabilities	843,022,174	500,216,678
Other non-current provisions	573,487,550	568,327,916
Total liabilities	175,525,589,638	204,321,935,802
Equity		
Issued capital	37,229,090,000	14,628,373,000
Capital surplus	746,773,512,890	549,031,241,883
Retained earnings (deficit)	-451,262,260,083	-406,927,840,497
Total equity	332,740,342,807	156,731,774,386
Total equity and liabilities	508,265,932,445	361,053,710,188

6. Separate Statements of Comprehensive Income

(Unit: KRW)

	1H 2026	1H 2025
Revenue	14,535,592,471	12,617,368,632
Operating expense	46,480,730,467	51,855,256,940
Operating income(loss)	-31,945,137,996	-39,237,888,308
Finance income	12,105,700,004	25,838,162,380
Finance costs	24,406,969,153	17,631,668,280
Other gains	21,881,824	66,918,071
Other losses	53,118,168	27,390,493
Profit (loss) before tax	-44,277,643,489	-30,991,866,630
Tax expense (income)	40,342,585	-1,327,392
Profit (loss)	-44,317,986,074	-30,990,539,238
Other comprehensive income	-16,433,512	-35,322,514
Other comprehensive income that will not be reclassified to profit or loss, net of tax	-16,433,512	-35,322,514
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-16,433,512	-35,322,514
Comprehensive income	-44,334,419,586	-31,025,861,752
Earnings per share		
Basic earnings (loss) per share	-659	-533
Diluted earnings (loss) per share	-659	-632

7. Separate Statements of Changes in Equity

(Unit: KRW)

	Separate	Issued capital	Elements of other stockholders equity	Retained earnings
1H 2026				
Statement of changes in equity				
Equity at beginning of period	156,731,774,386	14,628,373,000	549,031,241,883	-406,927,840,497
Increase (decrease) through transactions with owners, equity	220,342,988,007	22,600,717,000	197,742,271,007	0
Increase (decrease) through exercise of warrants, equity	933,527,670	51,650,000	881,877,670	0
Increase (decrease) through share-based payment transactions, equity	10,278,882,982	0	10,278,882,982	0
Issue of equity	209,130,577,355	3,953,408,000	205,177,169,355	0
Bonus issue	0	18,595,659,000	-18,595,659,000	0
Comprehensive income	-44,334,419,586	0	0	-44,334,419,586
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-16,433,512	0	0	-16,433,512
Profit (loss)	-44,317,986,074	0	0	-44,317,986,074
Equity at end of period	332,740,342,807	37,229,090,000	746,773,512,890	-451,262,260,083
1H 2025				
Statement of changes in equity				
Equity at beginning of period	175,010,809,970	14,471,450,000	526,645,689,887	-366,106,329,917
Increase (decrease) through transactions with owners, equity	11,263,194,550	103,509,000	11,159,685,550	0
Increase (decrease) through exercise of warrants, equity	2,286,084,380	103,509,000	2,182,575,380	0
Increase (decrease) through share-based payment transactions, equity	8,977,110,170	0	8,977,110,170	0
Issue of equity	0	0	0	0
Bonus issue	0	0	0	0
Comprehensive income	-31,025,861,752	0	0	-31,025,861,752
Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans	-35,322,514	0	0	-35,322,514
Profit (loss)	-30,990,539,238	0	0	-30,990,539,238
Equity at end of period	155,248,142,768	14,574,959,000	537,805,375,437	-397,132,191,669

8. Separate Statements of Cash Flows

(Unit: KRW)

	1H 2026	1H 2025
Cash flows from (used in) operating activities	-30,933,940,022	-27,427,175,830
Cash flows from (used in) operations	-28,748,180,503	-27,560,838,569
Interest received	160,584,259	465,546,221
Interest paid	-2,427,262,466	-919,689,793
Income taxes paid (refund), classified as operating activities	80,918,688	587,806,311
Cash flows from (used in) investing activities	-30,170,337,017	2,944,945,686
Inflows of cash from investing activities	9,547,168,593	12,435,896,761
Proceeds from sales of short term Financial Instruments	0	5,000,000,000
Proceeds from sales of property, plant and equipment	77,540,000	37,114,525
Decrease in other guarantee deposit	100,206,108	20,178,301
Proceeds from sales of fair value financial asset	9,369,422,485	7,378,603,935
Outflows of cash from investing activities	-39,717,505,610	-9,490,951,075
Purchase of property, plant and equipment	-70,473,909	-212,317,876
Purchase of intangible assets	-8,089,926,109	-82,266,000
Cash advances and loans made to other parties	-331,622,708	-390,460,799
Purchase of fair value financial asset	-30,111,566,884	-8,145,600,000
Purchase of investments in subsidiaries	-1,113,916,000	-660,306,400
Cash flows from (used in) financing activities	189,538,293,298	13,414,766,711
Inflows of cash from financing activities	240,064,105,025	14,286,084,380
Proceeds from exercise of share options	933,527,670	2,286,084,380
Proceeds from short term borrowings	30,000,000,000	12,000,000,000
Proceeds from issue of ordinary shares	209,130,577,355	0
Outflows of cash from financing activities	-50,525,811,727	-871,317,669
Payments of finance lease liabilities	-1,012,665,220	-871,317,669
Repayments of short term borrowings	-30,000,000,000	0
Repayments of convertible bonds	-19,513,146,507	0
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	128,434,016,259	-11,067,463,433
Cash and cash equivalents at beginning of period	4,417,207,942	40,764,729,065
Effect of exchange rate changes on cash and cash equivalents	434,435,106	-288,416,229
Cash and cash equivalents at end of period	133,285,659,307	29,408,849,403

Thank You

IR & Governance Team

Website

www.lunit.io

Email

ir@lunit.io